Halted trial tests new shot at taming hepatitis b
NCT ID NCT02452528
Summary
This study tested whether adding a new intravenous drug called ARC-520 to standard oral medications (entecavir or tenofovir) could more effectively reduce the amount of Hepatitis B virus in the body. It involved a small group of adults with a specific type of chronic Hepatitis B infection. The trial was terminated early, so its full results are unknown.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
San Francisco, California, 94118, United States
-
Research Site 2
Miami, Florida, 33136, United States
-
Research Site 4
New York, New York, 10029, United States
-
Research Site 6
San Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.